These mechanisms occur within hours after GCs administration and may lead to hyperglycemia, even in individuals without a prior history of glucose abnormalities ( Figure 1 The clinical impact of hyperglycemia during GCs therapy has been well established, with multiple studies reporting increased morbidity and mortality, including higher rates of infection, cardiovascular events and prolonged hospitalisations ( Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are not currently recommended in SID by major guidelines, their mechanism of action makes them promising candidates to counteract the metabolic impacts of steroids
Do not inject in the same spot two weeks in a row
Then: "How much weight are you looking to lose?" Answering these gets you to an online shopping page a dozen links to buy Ozempic, Wegovy, Mounjaro, in different forms
To date, no prospective clinical study of drug treatment has completed a comprehensive assessment of clinical benefits in MASLD
In the ACHIEVE-1 study, a 36 mg dose resulted in a reduction in HbA1c of 1.31.6% from a baseline of 8.0%, and an average weight loss of 7.9% (approximately 16.0 lbs) over 40 weeks
Licensed injectable GLP-1 formulations in the UK include once-daily liraglutide and once-weekly semaglutide and dulaglutide
